This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
by Zacks Equity Research
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Top Analyst Reports for Bank of America, Amgen & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Amgen (AMGN) and NextEra Energy (NEE).
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
by Zacks Equity Research
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
by Zacks Equity Research
Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
by Zacks Equity Research
Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta
by Zacks Equity Research
Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
by Zacks Equity Research
Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
The Zacks Analyst Blog Highlights: Apple, Amgen, United Technologies, Travelers and Xilinx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Amgen, United Technologies, Travelers and Xilinx
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
Top Research Reports for Apple, Amgen & United Technologies
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Amgen (AMGN) and United Technologies (UTX).
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
by Zacks Equity Research
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Roche Gets Approval for Label Expansion of MabThera in Europe
by Zacks Equity Research
Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
Roche Receives EC Approval for Label Expansion of Hemlibra
by Zacks Equity Research
Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval
by Zacks Equity Research
FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.
Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Is Amgen (AMGN) a Profitable Pick ForValue Investors Now?
by Zacks Equity Research
Amgen (AMGN) stock may be a good choice for value-oriented investors right now from multiple angles.